We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Focus of Quality Metrics is Surveillance, Not Enforcement
FDA: Focus of Quality Metrics is Surveillance, Not Enforcement
The FDA is trying to reassure drug companies by making it clear that the agency won’t use its quality metrics collection to spur 483s, warning letters and other enforcement actions.